1

2015 1. Selle F, Pautier P, Lhommé C, Viens P, Fabbro M, Lokiec F, Gligorov J, Richard S,

Provent S, Soares DG, Lotz JP. A phase I trial of high-dose chemotherapy combining topotecan plus cyclophosphamide with hematopoietic stem-cell transplantation for ovarian cancer: the ITOV 01bis study. Chemotherapy. 2015 Nov 4;61(1):15-22. [Epub ahead of print]

2. Selle F, Emile G, Pautier P, Asmane I, Soares DG, Khalil A, Alexandre J, Lhommé C, Ray-Coquard I, Lotz JP, Goldwasser F, Tazi Y, Heudel P, Pujade-Lauraine E, Gouy S, Tredan O, Barbaza MO, Ady-Vago N, Dubot C. Safety of bevacizumab in clinical practice for recurrent ovarian cancer: a retrospective cohort study. Oncol Lett. 2015 Nov, 9 [Epub ahead of print].

3. Selle F, Soares DG, Lotz JP. A rational approach for salvage of testicular cancer patients. Ann Oncol. 2015 Oct 19. pii: mdv492. [Epub ahead of print].

4. Richard S, Selle F, Lotz JP, Khalil A, Gligorov J, Soares DG. Pertuzumab and trastuzumab: the rationale way to synergy. An Braz Acad Sci. 2015 Oct, in press.

5. Selle F, Gligorov J, Richard S, Khalil A, Alexandre I, Avenin D, Provent S, Soares DG, Lotz JP. Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. Braz J Med Biol Res. 2015 Jan;48(1):13-24.

6. Rocca CJ, Soares DG, Bouzid H, Henriques JA, Larsen AK, Escargueil AE. BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle. 2015;14(13):2080-90.

7. Gligorov J, Richard S. Breast cancer: Weekly paclitaxel-still preferred first-line taxane for mBC. Nat Rev Clin Oncol. 2015 Sep;12(9):508-9. doi: 10.1038/nrclinonc.2015.137. Epub 2015 Aug 11.

8. DG Soares, J Michels, J Hadoux, A Bellesoeur, C Tlemsani, M.-A Benderra, JP Lotz. Compte Rendu/Report Congrès de l’association américaine de recherche contre le cancer—AACR 201. Oncologie 07/2015; 17(277):298. DOI:10.1007/s10269-015-2535-y

9. DG Soares, JP Lotz. Editorial. AACR 2015 : les avancées et les défis de la médecine personnalisée. Oncologie 07/2015; 17:275-276. DOI:10.1007/s10269-015-2531-2

10. Selle F, Gligorov J, Khalil A, Richard S, Provent S, Soares DG, Lotz JP. Chimiotherapie a hautes-doses et greffe de cellules souches hematopoïetiques pour contourner la resistance aux medicaments dans les tumeurs solides. Bull Cancer. 2015 Sept, Submitted.

11. Johanne Daupin, Pascal Paubel, Julie Fillon, Isabelle Debrix, Daniele G. Soares, Jean-Pierre Lotz.Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution. Journal of Chemotherapy, 2015 Submitted

2

12. Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo, Alain Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F. Volasertib versus Chemotherapy in Platinum-Resistant or Refractory Ovarian Cancer: Findings from a Randomized Phase II study. J Clin Oncol. 2015 Accepted. Manuscript number 7792

13. Nayi Zongo, A. Sanou, S. Ouédraogo, F. Djiwa, E. Ouangré, M. Zida, A. Ouédraogo, P.-G. Bonkoungou, A.-T. Bambara, A.-H. Bambara, S.-S. Traoré, DG. Soares, J-P Lotz. Cancer digestifs primitifs du suget âgé : particularités épidémiologiques dans un pays à faible epérance de vie : cas du Burkina Faso. Le JOG - Le Journal d’OncoGériatrie. Volume 6 - n°19 2 - avril-juin 2015

14. Poveda A, Selle F, Hilpert F, Reuss A, Pašić A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E, on behalf of the GINECO-ENGOT-GCIG Investigators. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol. 2015 Aug 17. pii: JCO.2015.63.1408. [Epub ahead of print]

15. Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F; French Sarcoma Group. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 Apr;16(4):457-64.

16. Heudel PE, Selle F, Morice P, Rouzier R, Taieb S, Devouassoux-Shisheboran M, Genestie C, Balleyguier C, Ray-Coquard I. [Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?] Bull Cancer. 2015 May 28. pii: S0007-4551(15)00150-2.

17. Cutuli B, Dalenc F, Cottu PH, Gligorov J, Guastalla JP, Petit T, Amrate A. Impact of screening on clinicopathological features and treatment for invasive breast cancer: Results of two national surveys. Cancer Radiother. 2015 Aug;19(5):295-302.

18. Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. Oncologist. 2015 Aug;20(8):873-9.

19. Margulies AL, Selleret L, Zilberman S, Nagarra IT, Chopier J, Gligorov J, Berveiller P, Ballester M, Darai E, Chabbert-Buffet N. [Pregnancy after cancer: for whom and when?]. Bull Cancer. 2015 May;102(5):463-9.

20. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015 May;26(5):873-9.

3

21. Talbot JN, Gligorov J, Nataf V, Montravers F, Huchet V, Michaud L, Ohnona J, Balogova S, Cussenot O, Daraï E, Lotz JP, Kerrou K. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone. Q J Nucl Med Mol Imaging. 2015 Mar;59(1):4-17.

22. Gligorov J. Looking for predictive markers in breast cancer-authors' reply. Lancet Oncol. 2015 Jan; 16(1):e1-2.

23. Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res. 2015 Mar 15;21(6):1298-304.

24. Bolze PA, Riedl C, Massardier J, Lotz JP, You B, Schott AM, Hajri T, Golfier F. Mortality of gestational trophoblastic neoplasia with a FIGO score of 13 and higher. Am J Obstet Gynecol. 2015 Sep 30. pii: S0002-9378(15)01197-7. doi: 10.1016/j.ajog.2015.09.083. [Epub ahead of print]

25. Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol. 2015 Aug;26(8):1692-7.

26. Pham MH, Delestre L, Dewitte A, Wattez N, Lepretre F, Lansiaux A. Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion. Anticancer Res. 2015 Nov;35(11):5983-91.

4

2014 1- Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon

A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K,Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP. A Phase II Trial of High-Dose Chemotherapy (HDCT) Supported by Hematopoietic Stem Cell Transplantation (HSCT) in Germ-Cell Tumors (GCTs) Patients Failing Cisplatin-based Chemotherapy: The Multicentric TAXIF II Study. Ann Oncol. 2014 Jun 3. pii: mdu198.

2- Richard S, Baste-Rotllan N, Soares D.G, Selle F, Khalil A, Gligorov J, Avenin D, Provent S, Lotz JP. Chimiothérapie des tumeurs trophoblastiques gestationnelles à haut risque. Oncologie. 2014 DOI 10.1007/s10269-014-2402-2

3- Laas E, Luyckx M, De Cuypere M, Selle F, Daraï E, Querleu D, Rouzier R, Chéreau E. Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system. Int J Gynecol Cancer. 2014 Feb;24(2):238-46. doi: 10.1097/IGC.0000000000000051.

4- Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain. 2014 Mar;15(3):293-303. doi: 10.1016/j.jpain.2013.11.004. Epub 2013 Dec 21.

5- Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane based chemotherapy in operable triple negative breast cancer: Identification of biologically-defined signatures predicting treatment impact. Ann Oncol. 2014 May 14. pii: mdu183. [Epub ahead of print].

6- Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; on behalf of the PrefHer Study Group; on behalf of the PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Jul 28. pii: mdu364. [Epub ahead of print]

7- Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. Ann Oncol, 2014 doi:10.1093/annonc/mdu392. [Epub ahead of print]

8- Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol, 2014 Sep 26. pii: S1470-2045(14)70444-9.

5

9- von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol, 2014 Oct;15(11):1269-78.

10- Poveda A, Selle F, Hilpert F, Reuss A, Pašić A, Savarese A, Vergote I, Witteveen P, Bamias A, Bollag D. Efficacy and safety of bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomised phase 3 AURELIA trial. Lancet Oncol, 2014. Submitted

11- Selle F, Gligorov J, Khalil A, Richard S, Avenin D, Esteso A, Provent S, Soares D.G, Lotz JP. Chimiothérapie a haute-doses et greffe autologue de cellules souches hematopoïetiques dans les tumeurs solides. Submitted, 2014.

12- Selle F, Gligorov G, Richard S, Khalil A, Alexandre I, Avenin D, Provent S, Soares DG, Lotz JP. Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. Braz J Med Biol Res, 2014, 48(1):13-24 [Epub ahead of print].

13- Selle F, Emile G, Pautier P, Asmane I, Soares DG, Khalil A, Alexandre J, Lhommé C, Ray Coquard I, Lotz JP, Goldwasser F, Tazi Y, Heudel P, Pujade-Lauraine E, Gouy S, Tredan O, Barbaza MO, Ady-Vago N , Dubot C. Safety of bevacizumab in clinical practice for recurrent ovarian cancer: a retrospective cohort study. Oncology Reports, Accepted 2014.

14- Selle F, et al. A phase i study of high-dose chemotherapy combining topotecan plus cyclophosphamide supported by hematopoietic stem-cell transplantation for poor prognosis ovarian cancer patients: the ITOV 01bis protocol. Submitted, 2014.

6

2013 1- Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund

P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; Lotz JP; ML18147 study investigators

including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT

groups. Bevacizumab plus chemotherapy continued beyond first progression in patients

with metastatic colorectal cancer previously treated with bevacizumab plus

chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol, 24(9):2342-9,

2013.

2- Lévy P, Gligorov J, Antoine M, Rezai K, Lévy E, Selle F, Saintigny P, Lokiec F, Avenin D,

Beerblock K, Lotz JP, Bernaudin JF, Fajac A. Influence of ABCB1 polymorphisms and

docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in

breast cancer patients. Breast Cancer Res Treat, 139(2):421-8, 2013.

3- Popovic L, Jovanovic D, Donat D, Petrovic D, Roganovic T, Lotz JP. High dose

chemotherapy with autologous stem cell transplantation for patients with germ-cell

cancer. J BUON, 18(1):290-1, 2013.

4- Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez

JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I,

Bendahmane B, André T, Kubicka S; Lotz JP; ML18147 Study Investigators. Continuation

of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a

randomised phase 3 trial. Lancet Oncol, 14(1):29-37, 2013.

5- Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-

Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De

Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD,

Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A,

Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S,

Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J,

Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G,

Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T,

Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on

survivorship: highlights from the third European consensus conference on diagnosis and

treatment of germ-cell cancer. Ann Oncol, 24(4):878-88, 2013.

6- Thariat J, Schouman T, Brouchet A, Sarini J, Miller RC, Reychler H, Ray-Coquard I,

Italiano A, Verite C, Sohawon S, Bompas E, Dassonville O, Salas S, Aldabbagh K,

Maingon P, de La MotteRouge T, Kurtz JE, Usseglio J, Kerbrat P, Raoul G, Lotz JP, Bar-

Sela G, Brugières L, Chaigneau L, Saada E, Odin G, Marcy PY, Thyss A, Julieron M.

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the

young adult a cooperative study of the GSF-GETO, Rare Cancer Network,

GETTEC/REFCOR and SFCE. Ann Oncol, 24(3):824-31, 2013.

7- Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart

A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria

JC, Sahmoud T, André F. A phase 2 study of everolimus combined with trastuzumab and

paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed

during prior trastuzumab and taxane therapy. Breast Cancer Res Treat, 141(3):437-

46, 2013.

7

8- Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov

V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group.

Preference for subcutaneous or intravenous administration of trastuzumab in patients

with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Lancet Oncol, 14(10):962-70, 2013.

9- Séroussi B, Laouénan C, Gligorov J, Uzan S, Mentré F, Bouaud J. Which breast cancer

decisions remain non-compliant with guidelines despite the use of computerised decision

support? Br J Cancer, 109(5):1147-56, 2013.

10- Robert T, Moktefi A, Wiig H, Brochériou I, Michaud L, Gligorov J, Finianos S, Hertig A.

Acute kidney failure with renal carcinomatous lymphangitis secondary to advanced colon

cancer. Kidney Int, 84(2):420, 2013.

11- Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M,

Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-

Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; Gligorov J, Avenin D,

PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for

patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Lancet Oncol, 14(8):741-8, 2013.

12- Thibault C, Khodari W, Lequoy M, Gligorov J, Belkacémi Y. HER2 status for prognosis

and prediction of treatment efficacy in adenocarcinomas: a review. Crit Rev Oncol

Hematol, 88(1):123-33, 2013.

13- Lagha A, Chraiet N, Labidi S, Krimi S, Ayadi M, Gligorov J, Boussen H. [Impact of

taxanes in the adjuvant setting of node-negative breast cancers]. Bull Cancer

100(5):465-71, 2013.

14- Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA,

Kyriakides S, Pagani O, Senkus E, Costa A, Gligorov J, Winer EP; ESO-MBC Task Force.

International guidelines for management of metastatic breast cancer (MBC) from the

European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and

evaluation of patients with early-stage and metastatic breast cancer. Breast, 22(3):203-

10, 2013.

15- Touboul C, Bezu C, Daraï E, Chopier J, Touboul E, Gligorov J, Rouzier R, Uzan S. [Are

decisions of multidisciplinary tumor boards in accordance with the guidelines?

Experience of an university reference center for breast cancer]. Gynecol Obstet Fertil,

41(3):164-7, 2013.

16- Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F,

Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux

A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder

C, Lhommé C, Rey A. A randomized clinical trial of adjuvant chemotherapy with

doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy

alone in patients with localized uterine sarcomas (SARCGYN study). A study of the

French Sarcoma Group. Ann Oncol, 24(4):1099-104, 2013.

8

2012 1- Gerotziafas GT, Galea V, Mbemba E, Sassi M, Roman MP, Khaterchi A, van Dreden P,

Japcowitz M, Lotz JP, Bernaudin JF, Fareed J, Hatmi M, Elalamy I. Effect of Low

Molecular Weight Heparins and Fondaparinux upon Thrombin Generation Triggered

by Human Pancreatic Cancer Cells BXPC3. Curr Vasc Pharmacol Jun 22, 2012.

2- Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, Lotz JP; IES Steering

Committee. Carpal tunnel syndrome and musculoskeletal symptoms in

postmenopausal women with early breast cancer treated with exemestane or

tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup

Exemestane Study. Lancet Oncol 13(4):420-32, 2012.

3- Bui-Nguyen B, Ray-Coquard I, Chevreau C, Penel N, Bay JO, Coindre JM, Cupissol D,

Italiano A, Bonichon F, Lotz JP, Thyss A, Jimenez M, Mathoulin-Pélissier S, Blay JY;

GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for

chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized

controlled trial. Ann Oncol, 23(3):777-84, 2012.

4- Belkacémi Y, Boussen H, Turkan S, Tsoutsou PG, Geara F, Gligorov J. Fight against

cancer around the Mediterranean area: "Many hands make light work!" Crit Rev

Oncol Hematol, 84 Suppl 1:e1-5, 2012.

5- Vataire AL, Laas E, Aballéa S, Gligorov J, Rouzier R, Chéreau E. [Cost-effectiveness of

a chemotherapy predictive test]. Bull Cancer, 99(10):907-14, 2012.

6- Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann

Oncol, 23 Suppl 6:vi40-5, 2012.

7- Laas E, Vataire AL, Aballea S, Valentine W, Gligorov J, Chereau E, Rouzier R.

Evaluation of the costs and resource use associated with adjuvant chemotherapy for

breast cancer in France. J Med Econ, 15(6):1167-75, 2012.

8- Chéreau E, Bezu C, Gligorov J, Sakr R, Antoine M, Daraï E, Uzan S, Rouzier R. Impact

of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer

management. Anticancer Res, 32(8):3403-9, 2012.

9- Genin AS, Lesieur B, Gligorov J, Antoine M, Selleret L, Rouzier R. Pregnancy-

associated breast cancers: do they differ from other breast cancers in young women?

Breast, 21(4):550-5, 2012.

10- Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N,

Mitchell L, Tjulandin S. Phase II study of bevacizumab in combination with

trastuzumab and capecitabine as first-line treatment for HER-2-positive locally

recurrent or metastatic breast cancer. Oncologist, 17(4):469-75, 2012.

11- Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov

J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A,

El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C,

Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't

Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced

breast cancer (ABC 1). Breast, 21(3):242-52, 2012.

12- Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché

H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P.

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory

HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

Lancet Oncol, 13(4):375-84, 2012.

9

13- Frati A, Chereau E, Coutant C, Bezu C, Antoine M, Chopier J, Daraï E, Uzan S,

Gligorov J, Rouzier R. Comparison of two nomograms to predict pathologic complete

responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-

positive tumors need specific predictors. Breast Cancer Res Treat, 132(2):601-7,

2012.

14- Gligorov J, Launay-Vacher V, Aapro M. [Treatments of metastases in cancer]. Bull

Cancer, 1;99(3):333-43, 2012.

15- Beuzeboc P, Le Tourneau C, Gligorov J, Janus N, Spano JP, Ray-Coquard I, Deray G,

Launay-Vacher V. [Renal insufficiency and breast cancer]. Bull Cancer, 99(3):309-

15, 2012.

16- Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson

B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E,

Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a

pragmatic definition and implications for patient management and trial design.

Breast, 21(1):20-6, 2012.

17- Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T,

Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-

Fournier C, Joly F. Expected benefits of topotecan combined with lapatinib in

recurrent ovarian cancer according to biological profile: a phase 2 trial. Int J

Gynecol Cancer, 22(9):1483-8, 2012.

18- Revaux A, Rouzier R, Ballester M, Selle F, Daraï E, Chéreau E. Comparison of

morbidity and survival between primary and interval cytoreductive surgery in patients

after modified posterior pelvic exenteration for advanced ovarian cancer. Int J

Gynecol Cancer, 22(8):1349-54, 2012.

19- Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. [Clues for paraaortic

lymphadenectomy in patients older than 70 years with ovarian cancer]. Gynecol

Obstet Fertil, 40(5):327-9, 2012.

10

2011 1- Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M,

Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T.

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in

metastatic breast cancer: overview of six randomized trials. J Clin Oncol,

20;29(24):3224-31, 2011.

2- Coussy F, Chéreau E, Daraï E, Dhombres F, Lotz JP, Rouzier R, Selle F. [Interest of

CA 125 level in management of ovarian cancer]. Gynecol Obstet Fertil, 39(5):296-

301, 2011.

3- Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U,

Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer

J. Conventional-dose versus high-dose chemotherapy as first salvage treatment in

male patients with metastatic germ cell tumors: evidence from a large international

database. J Clin Oncol, 29(16):2178-84, 2011.

4- Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy

J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F,

Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J,

Gligorov J; Breast Cancer International Research Group. Adjuvant trastuzumab in

HER2-positive breast cancer. N Engl J Med, 365(14):1273-83, 2011.

5- Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A, Gligorov J, Facchini T, Jaubert

D, Maille N, Pivot X, Grangé V, Cals L. Myotax: a phase II trial of docetaxel plus non-

pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer

previously treated with adjuvant anthracyclines. Eur J Cancer, 47(16):2396-402,

2011.

6- Frati A, Antoine M, Rodenas A, Gligorov J, Rouzier R, Chéreau E. [Somatostatin in

breast cancer]. Ann Biol Clin (Paris), 69(4):385-91, 2011.

7- Decanter C, Gligorov J. [Oocyte/embryo cryopreservation before chemotherapy for

breast cancer]. Gynecol Obstet Fertil, 39(9):501-3, 2011.

8- Penault-Llorca F, Coeffic D, Delozier T, Dohollou N, Freyer G, Gligorov J, Hardy-

Bessard AC, Jacot W, Misset JL, Nabholtz JM, Petit T, Spielmann M, Namer M. [Node

negative breast cancer. Beyond international consensus: a pragmatic approach]. Bull

Cancer, 98(7):807-25, 2011.

9- Gligorov J, Fajac A, Bernaudin JF. Castration-dependent pharmacokinetics of

docetaxel: do sex and/or ABCB1 polymorphism also matter? J Clin Oncol,

29(15):e454-5, 2011.

10- Chéreau E, Coutant C, Gligorov J, Lesieur B, Antoine M, Daraï E, Uzan S, Rouzier R.

Discordance with local guidelines for adjuvant chemotherapy in breast cancer:

reasons and effect on survival. Clin Breast Cancer, 11(1):46-51, 2011.

11- Rouzier R, Werkoff G, Uzan C, Mir O, Gligorov J, Selleret L, Goffinet F, Goldwasser F,

Treluyer JM, Uzan S, Delaloge S. Pregnancy-associated breast cancer is as

chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant

setting. Ann Oncol, 22(7):1582-7, 2011.

12- Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L,

Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert

B. Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated

by anthracycline-free neoadjuvant chemotherapy. Ann Oncol, 22(2):321-8, 2011.

11

13- Belkacémi Y, Fourquet A, Cutuli B, Bourgier C, Hery M, Ganem G, Marsiglia H, Namer

M, Gligorov J, Azria D; French Expert Review Board of Nice/Saint-Paul de Vence.

Radiotherapy for invasive breast cancer: guidelines for clinical practice from the

French expert review board of Nice/Saint-Paul de Vence. Crit Rev Oncol Hematol,

79(2):91-102, 2011.

14- Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B,

Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B,

Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI, Gligorov

J; ATHENA Study Group. First-line bevacizumab plus taxane-based chemotherapy for

locally recurrent or metastatic breast cancer: safety and efficacy in an open-label

study in 2,251 patients. Ann Oncol, 22(3):595-602, 2011.

15- Gligorov J, Bastit L, Gervais H, Henni M, Kahila W, Lepille D, Luporsi E, Sasso G,

Varette C, Azria D; Candidoscope Study Group. Prevalence and treatment

management of oropharyngeal candidiasis in cancer patients: results of the French

CANDIDOSCOPE study. Int J Radiat Oncol Biol Phys, 80(2):532-9, 2011.

16- AROME. Guidelines, minimal requirements and standard of cancer care around the

Mediterranean Area: report from the Collaborative AROME (Association of

Radiotherapy and Oncology of the Mediterranean Area) working parties. Crit Rev

Oncol Hematol, 78(1):1-16, 2011.

17- Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G,

Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle

A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A,

Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. A phase 3 trial

of bevacizumab in ovarian cancer. N Engl J Med, 365(26):2484-96, 2011.

18- Chéreau E, Lavoue V, Ballester M, Coutant C, Selle F, Cortez A, Daraï E, Leveque J,

Rouzier R. External validation of a laparoscopic-based score to evaluate resectability

for patients with advanced ovarian cancer undergoing interval debulking surgery.

Anticancer Res. 2011 Dec;31(12):4469-74.

19- Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. Ovarian cancer in the elderly:

impact of surgery on morbidity and survival. Eur J Surg Oncol, 37(6):537-42, 2011.

20- Chéreau E, Ballester M, Lesieur B, Selle F, Coutant C, Rouzier R, Daraï E.

[Complications of radical surgery for advanced ovarian cancer]. Gynecol Obstet

Fertil, 39(1):21-7, 2011.

12

2010 1- International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C,

Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA,

Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. Prognostic factors in

patients with metastatic germ cell tumors who experienced treatment failure with

cisplatin-based first-line chemotherapy. J Clin Oncol, 28(33):4906-11, 2010.

2- Ray-Coquard I, Weber B, Lotz JP, Tournigand C, Provencal J, Mayeur D, Treilleux I,

Paraiso D, Duvillard P, Pujade-Lauraine E; GINECO group. Management of rare

ovarian cancers: the experience of the French website "Observatory for rare

malignant tumours of the ovaries" by the GINECO group: interim analysis of the first

100 patients. Gynecol Oncol, 119(1):53-9, 2010.

3- Tsoutsou PG, Belkacemi Y, Gligorov J, Kuten A, Boussen H, Bese N, Koukourakis MI;

Association of Radiotherapy and Oncology in the Mediterranean area (AROME).

Optimal sequence of implied modalities in the adjuvant setting of breast cancer

treatment: an update on issues to consider. Oncologist, 15(11):1169-78, 2010.

4- Belkacémi Y, Gligorov J, Chauvet MP, Tsoutsou PG, Boussen H, Bourgier C.

[Radiotherapy and combined therapy in breast cancer: standards and innovations in

the adjuvant setting]. J Gynecol Obstet Biol Reprod (Paris), 39(8 Suppl):F63-9,

2010.

5- Mouridsen HT, Lonning P, Beckmann MW, Blackwell K, Doughty J, Gligorov J,

Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M. Use of aromatase inhibitors

and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.

Expert Rev Anticancer Ther, 10(11):1825-36, 2010.

6- Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni

J, Gligorov J, Grygar C, Marcu M, Triebel F. First-line chemoimmunotherapy in

metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig)

enhances immune responses and antitumor activity. J Transl Med, 8:71, 2010.

7- Fajac A, Gligorov J, Rezai K, Lévy P, Lévy E, Selle F, Beerblock K, Avenin D, Saintigny

P, Hugonin S, Bernaudin JF, Lokiec F. Effect of ABCB1 C3435T polymorphism on

docetaxel pharmacokinetics according to menopausal status in breast cancer patients.

Br J Cancer, 103(4):560-6, 2010.

8- Bendifallah S, Werkoff G, Borie-Moutafoff C, Antoine M, Chopier J, Gligorov J, Uzan S,

Coutant C, Rouzier R. Multiple synchronous (multifocal and multicentric) breast

cancer: clinical implications. Surg Oncol, 19(4):e115-23, 2010.

9- Chabbert-Buffet N, Uzan C, Gligorov J, Delaloge S, Rouzier R, Uzan S. Pregnancy

after breast cancer: a need for global patient care, starting before adjuvant therapy.

Surg Oncol, 19(1):e47-55, 2010.

10- Belkacémi Y, Gligorov J. Concurrent trastuzumab--internal mammary irradiation for

HER2 positive breast cancer: "It hurts to be on the cutting edge". Radiother Oncol,

94(1):119-20, 2010.

11- Belkacémi Y, Boussen H, Gligorov J. [Mediterranean collaboration in the fight against

cancer: "it is as if the past had never existed"]. Bull Cancer, 97(4):407-8, 2010.

12- Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I,

Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P; Renal Insufficiency and

Anticancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in

13

breast cancer patients and related pharmacological issues. Breast Cancer Res

Treat, 124(3):745-53, 2010.

13- Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Daraï E. Wound complications

after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer

Res, 30(11):4743-7, 2010.

14- Rouzier R, Bergzoll C, Brun JL, Dubernard G, Selle F, Uzan S, Pomel C, Daraï E. The

role of lymph node resection in ovarian cancer: analysis of the Surveillance,

Epidemiology, and End Results (SEER) database. BJOG, 117(12):1451-8, 2010.

15- Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, Falandry C, Lebrun

D, Pujade-Lauraine E; GINECO. Mucinous advanced epithelial ovarian carcinoma:

clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the

GINECO experience. Ann Oncol, 21(12):2377-81, 2010.

16- Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R. Comparison of

peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in

advanced ovarian cancer. Am J Obstet Gynecol, 202(2):178.e1-178.e10, 2010.

17- Ray-Coquard I, Pautier P, Pujade-Lauraine E, Méeus P, Morice P, Treilleux I, Duvillard

P, Alexandre J, Lhommé C, Selle F, Guastalla J. [Rare ovarian tumours: therapeutic

strategies in 2010, national website observatory for rare ovarian cancers and

delineation of referent centers in France]. Bull Cancer, 97(1):123-35, 2010.

14

2009 1- Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H,

Chaput N, Barrou B, Thioun N, Gattegnio B, Selles F, Six A, Azar N, Lotz JP, Buzyn A,

Sibony M, Delcourt A, Boyer O, Herson S, Klatzmann D, Lacave R. Massive expansion

of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic

cell-based immunotherapy of metastatic renal cancer. Int J Oncol, 35(3):569-81,

2009.

2- Afqir S, Ismaili N, Alaoui K, Ahid S, Lotz JP, Horn E, Bouhafa T, Abouqal R, Errihani H.

Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur

Arch Otorhinolaryngol, 266(11):1767-73, 2009.

3- Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron

F, Bouchard P, Grangé JD, Houry S, Talbot JN. Impact of

fluorodihydroxyphenylalanine-18F positron emission tomography on management of

adult patients with documented or occult digestive endocrine tumors. J Clin

Endocrinol Metab, 94(4):1295-301, 2009.

4- Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X,

Morere JF, Beuzeboc P, Deray G, Oudard S; Renal Insufficiency and Anticancer

Medications (IRMA) Study Group. Drug management of prostate cancer: prevalence

and consequences of renal insufficiency. Clin Genitourin Cancer, 7(3):E83-9, 2009.

5- Largillier R, Savignoni A, Gligorov J, Chollet P, Guilhaume MN, Spielmann M, Luporsi

E, Asselain B, Coudert B, Namer M; GET(N)A Group. Prognostic role of pregnancy

occurring before or after treatment of early breast cancer patients aged <35 years: a

GET(N)A Working Group analysis. Cancer, 15;115(22):5155-65, 2009.

6- Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Gligorov J;

Panel members. Thresholds for therapies: highlights of the St Gallen International

Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol,

20(8):1319-29, 2009.

7- Gounant V, Milleron B, Assouad J, Gligorov J, Lavole A, Wislez M, Brian E, Bazelly B,

Grunenwald D. [Bevacizumab and invasive procedures: practical recommendations].

Rev Mal Respir, 26(2):221-6, 2009.

8- Azria D, Jacot W, Gligorov J, Belkacémi Y, Zaman K, Romieu G, Ozsahin M. [Adjuvant

breast cancer treatment with hormono-radiotherapy]. Bull Cancer, 96(3):285-9,

2009.

9- Gligorov J, Launay-Vacher V, Debrix I. [Osteonecrosis of the jaw and

bisphosphonates: current data and perspectives]. Rev Med Interne, 30(8):653-5,

2009.

10- Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, Samson J,

Lesclous P, Laredo JD, Namer M. Physiopathology and management of osteonecrosis

of the jaws related to bisphosphonate therapy for malignant bone lesions. A French

expert panel analysis. Crit Rev Oncol Hematol, 71(1):12-21, 2009.

11- Launay-Vacher V, Spano JP, Janus N, Gligorov J, Ray-Coquard I, Oudard S, Pourrat X,

Morere JF, Beuzeboc P, Deray G; Renal Insufficiency and Anticancer Medications

(IRMA) Study Group. Renal insufficiency and anticancer drugs in elderly cancer

patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol,

70(2):124-33, 2009.

15

12- Brun JL, Rouzier R, Selle F, Houry S, Uzan S, Daraï E. Neoadjuvant chemotherapy or

primary surgery for stage III/IV ovarian cancer: contribution of diagnostic

laparoscopy. BMC Cancer, 6;9:171, 2009.

13- Chéreau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E, Rouzier R. Pulmonary

morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG,

116(8):1062-8, 2009.

14- Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF,

Mineur L, Artru P, André T, Louvet C. First-line simplified GEMOX (S-GemOx) versus

classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR

randomized phase II study. Bull Cancer, 96(5):E18-22, 2009.

15- Chéreau E, Stefanescu D, Selle F, Rouzier R, Daraï E. Spontaneous rectovaginal fistula

during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet

Gynecol, 200(1):e15-6, 2009.

16

2008 1- Avenin D, Selle F, Gligorov J, Japkowicz M, Houssel P, Carette B, Bernard M, Abbas F,

Khalil A, Bourayou N, Lokiec F, Carola E, Saint-Jean O, Leblond V, Bouvard E, Lotz JP.

[Chemotherapy in the elderly: how and for whom?]. Bull Cancer, 28;95 FMC

Onco:F28-36, 2008.

2- Debrix I, Avenin D, André T, Abbas F, Gligorov J, Milleron B, Lotz JP, Becker A.

[Anticancer chemotherapy in the elderly: a review of the literature]. Bull Cancer,

28;95 FMC Onco:F37-43, 2008.

3- Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with

hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast

Cancer Res Treat, 112 Suppl 1:53-66, 2008.

4- Bernard M, Avenin D, Selle F, Gligorov J, Houssel P, Carette B, Bourayou N, Lokiec F,

Carola E, Lotz JP. [Chemotherapy-induced cardiotoxicity in the elderly]. Bull Cancer,

28;95 FMC Onco:F89-95, 2008.

5- Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D,

Pichon MF, Lipton A; Serum HER-2/neu Study Group. Serum HER-2/neu and relative

resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

Cancer, 15;113(6):1294-301, 2008.

6- Pivot X, Koralewski P, Hidalgo JL, Chan A, Gonçalves A, Schwartsmann G,

Assadourian S, Lotz JP. A multicenter phase II study of XRP6258 administered as a 1-

h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

Ann Oncol, 19(9):1547-52, 2008.

7- Theodore C, Chevreau C, Yataqhene Y, Fizazi K, Delord JP, Lotz JP, Geoffrois L,

Kerbrat P, Bui V, Flechon A. A phase II multicenter study of oxaliplatin in combination

with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for

germ-cell tumors. Ann Oncol, 19(8):1465-9, 2008.

8- Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M. [The use of

deodorants/antiperspirants does not constitute a risk factor for breast cancer]. Bull

Cancer, 95(9):871-80, 2008.

9- Belkacémi Y, Penault-Llorca F, Gligorov J, Azria D. [The use of breast cancer subtype

classification to predict local and distant recurrence. A review]. Cancer Radiother,

12(6-7):577-83, 2008.

10- Belkacémi Y, Gligorov J, Ozsahin M, Marsiglia H, De Lafontan B, Laharie-Mineur H,

Aimard L, Antoine EC, Cutuli B, Namer M, Azria D. Concurrent trastuzumab with

adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses

from the French multicentric study. Ann Oncol, 19(6):1110-6, 2008.

11- Azria D, Ozsahin M, Gligorov J, Zaman K, Llacer Moscardo C, Lemanski C, Jacot W,

Belkacémi Y. [How to combine hormonotherapy and radiation treatment in adjuvant

breast cancer?]. Cancer Radiother, 12(1):37-41, 2008.

12- Fédération nationale des centres de lutte contre le cancer (FNCLCC). [Standards,

Options: Recommendations for the management of patients with epithelial ovarian

cancer. Medical front-line treatment (summary report, update 2008)]. Gynecol

Obstet Fertil, 36(6):684-700, 2008.

13- André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR,

Louvet C, Perez N, Mehmud F, Scheithauer W. Gemcitabine and oxaliplatin in

17

advanced biliary tract carcinoma: a phase II study. Br J Cancer, 16;99(6):862-7,

2008.

14- André T. [Targeted therapies in oncology: an ambiguous terminology]. Rev Med

Interne, 30(5):391-2, 2009.

15- Milano G, Etienne-Grimaldi MC, Dahan L, Francoual M, Spano JP, Benchimol D, Chazal

M, Letoublon C, André T, Gilly FN, Delpero JR, Formento JL. Epidermal growth factor

receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol

19(12):2033-8, 2008.

16- Köhler K, Ganser A, André T, Roth G, Grosse-Hovest L, Jung G, Brock R. Stimulus

dependence of the action of small-molecule inhibitors in the CD3/CD28 signalling

network. Chem Med Chem, 3(9):1404-11, 2008.

17- O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T,

Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer:

findings from the ACCENT data set. J Clin Oncol, 10;26(14):2336-41, 2008.

18- Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B,

Tabernero J, Karaboué A, Domont J, Levi F, Rougier P. Cetuximab efficacy and safety

in a retrospective cohort of elderly patients with heavily pretreated metastatic

colorectal cancer. Crit Rev Oncol Hematol, 67(3):255-62, 2008.

19- Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, Lledo G,

Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C. Concomitant administration of

weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months

of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic

cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin

Oncol, 1;26(7):1080-5, 2008.

20- Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P,

André T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le

Guludec D. Early detection of recurrence by 18FDG-PET in the follow-up of patients

with colorectal cancer. Br J Cancer, 11;98(5):875-80, 2008.

21- Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi

B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile

JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic

factor in patients with advanced colorectal cancer treated with cetuximab. J Clin

Oncol, 20;26(3):374-9, 2008.

22- Bachet JB, Afchain P, Fermanian C, Bouchahda M, Mitry E, Landi B, André T, Lièvre A,

Louvet C, Aegerter P, Levi F, Rougier P. Cetuximab efficacy in patients treated

routinely in university hospitals. Gastroenterol Clin Biol, 31(11):941-9, 2007.

23- André T, Antonini M, Barlaud M, Gray RM. Entropy-based distortion measure and bit

allocation for wavelet image compression. IEEE Trans Image Process,

16(12):3058-64, 2007.

24- Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van

Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker

O, de Gramont A. Phase II trial of cetuximab in combination with fluorouracil,

leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J

Clin Oncol, 20;25(33):5225-32, 2007.

25- Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, Barcelo R,

Cervantes A, André T, Colin P, Louvet C, de Gramont A. FOLFOX in patients aged

18

between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of

the OPTIMOX1 study. Cancer, 15;110(12):2666-71, 2007.

26- André T, Tournigand C, Abbas F, Louvet C, de Gramont A; Gercor (French Oncology

Research Group). [Anti-angiogenic treatment and colorectal cancer]. Bull Cancer, 94

Spec No:S211-9, 2007.

27- Blanchard P, Huguet F, André T. [Gemcitabine and digestive carcinomas]. Bull

Cancer, 94 Spec No Actualites:S104-15, 2007.

28- André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P,

Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M,

de Gramont A. Phase III study comparing a semimonthly with a monthly regimen of

fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer

patients: final results of GERCOR C96.1. J Clin Oncol, 20;25(24):3732-8, 2007.

29- de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A,

Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I,

Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C. Reintroduction of

oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin

Oncol, 1;25(22):3224-9, 2007.

19

2007

1- Gligorov J, Selle F, Khalil A, Abbas F, Namer M, Lotz JP. [Updates on gemcitabine on

metastatic breast cancer]. Bull Cancer, 94 Spec No Actualites:S90-4, 2007.

2- Foïs E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, Fermand JP, Arnulf

B, Mounier N, Ertault M, Lotz JP, Galicier L, Raffoux E, Benbunan M, Marolleau JP,

Larghero J. Recovery, viability and clinical toxicity of thawed and washed

haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell

transplantations. Bone Marrow Transplant, 40(9):831-5, 2007.

3- Séroussi B, Bouaud J, Gligorov J, Uzan S. Supporting multidisciplinary staff meetings

for guideline-based breast cancer management: a study with OncoDoc2. AMIA Annu

Symp Proc, 11:656-60, 2007.

4- Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use of aromatase

inhibitors: reducing the risk of recurrence and distant metastasis. Breast, 16 Suppl

3:S1-9, 2007.

5- Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K,

Pylkkänen L, Pecherstorfer M, Aapro MS. Pathophysiology, risk factors and

management of bisphosphonate-associated osteonecrosis of the jaw: Is there a

diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol

Hematol, 64(3):198-207, 2007.

6- Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies

combining antihormonal and biological targeted therapies in breast cancer: focus on

clinical trials and perspectives. Crit Rev Oncol Hematol, 64(2):115-28, 2007.

7- Belkacémi Y, Laharie-Mineur H, Gligorov J, Azria D. [Potential risk and benefit of the

combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic

breast cancer]. Cancer Radiother, 11(5):266-75, 2007.

8- Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF,

Beuzeboc P, Deray G. Renal Insufficiency and Cancer Medications (IRMA) Study

Group. Prevalence of Renal Insufficiency in cancer patients and implications for

anticancer drug management: the renal insufficiency and anticancer medications

(IRMA) study. Cancer, 15;110(6):1376-84, 2007.

9- Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov

J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M.

Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and

carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or

III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol, 1;25(19):2678-84,

2007.

10- Toledano AH, Bollet MA, Fourquet A, Azria D, Gligorov J, Garaud P, Serin D, Bosset

JF, Miny-Buffet J, Favre A, LeFoch O, Calais G. Does concurrent radiochemotherapy

affect cosmetic results in the adjuvant setting after breast-conserving surgery?

Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.

Int J Radiat Oncol Biol Phys, 1;68(1):66-72, 2007.

11- Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E,

Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of

chemoradiotherapy after disease control with chemotherapy in locally advanced

20

pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol, Jan

20;25(3):326-31, 2007.

12- André T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, Louvet C, de

Gramont A. Current status of adjuvant therapy for colon cancer. Gastrointest

Cancer Res, 1(3):90-7, 2007.

13- de Gramont A, Tournigand C, André T, Larsen AK, Louvet C. Adjuvant therapy for

stage II and III colorectal cancer. Semin Oncol, 34 (2 Suppl 1):S37-40, 2007.

14- Deberne M, Huguet F, Le Scodan R, Hammel P, Andre T. [Adjuvant and neoadjuvant

treatment for pancreatic adenocarcinoma in 2006]. Bull Cancer, 94(1):72-80, 2007.

15- Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E,

Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of

chemoradiotherapy after disease control with chemotherapy in locally advanced

pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol,

20;25(3):326-31, 2007.

16- André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M,

Postel Vinay S, Bidard FC, Louvet C, de Gramont A; GERCOR (French Oncology

Research Group). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy

(OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann

Oncol, 18(1):77-81, 2007.

21

2006

1- Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F,

Grangé JD, Lotz JP, Talbot JN. Can fluorodihydroxyphenylalanine PET replace

somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J

Nucl Med, 47(9):1455-62, 2006.

2- Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion KM,

Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T; European Group for

Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. High dose

chemotherapy with autologous hematopoietic stem cell support for solid tumors

other than breast cancer in adults. Ann Oncol, 17(10):1479-88, 2006.

3- Gonçalves A, Delva R, Fabbro M, Gladieff L, Lotz JP, Ferrero JM, Linassier C, Cottu

PH, Viens P, Extra JM. Post-operative sequential high-dose chemotherapy with

haematopoietic stem cell support as front-line treatment in advanced ovarian cancer:

a phase II multicentre study. Bone Marrow Transplant, 37(7):651-9, 2006.

4- Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B,

Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève

J, Lhommé C; Groupe d' Intensification des traitements des Tumeurs Ovariennes

(ITOV Group). Phase I study of high-dose topotecan with haematopoietic stem cell

support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Bone

Marrow Transplant, 37(7):669-75, 2006.

5- Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP,

Belle SV, Extra JM, Cvitkovic E. A phase II study of a paclitaxel and oxaliplatin

combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann

Oncol, 17(3):429-36, 2006.

6- Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz

JP, Touboul E, Lacave R. Prognostic impact of multidrug resistance gene expression

on the management of breast cancer in the context of adjuvant therapy based on a

series of 171 patients. Br J Cancer, 27;94(4):473-80, 2006.

7- Marzetti G, Marret E, Lotz JP, Gattegno B, Bonnet F. Brachial plexus injury during

anaesthesia in patients receiving cisplatin-based chemotherapy. Eur J Anaesthesiol,

23(3):262-5, 2006.

8- Nabholtz JM, Gligorov J. The emerging role of aromatase inhibitors in the adjuvant

management of breast cancer. Rev Recent Clin Trials, 1(3):237-49, 2006.

9- Belkacémi Y, Gligorov J, Mauriac L, Azria D. [HER-2/neu positive breast cancer: how

to prescribe adjuvant trastuzumab (Herceptin)?]. Bull Cancer, 93(10):991-9, 2006.

10- Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a

comparative review. Drug Saf, 29(9):785-801, 2006.

11- Nabholtz JM, Gligorov J. Taxane therapy for early stage breast cancer. Womens

Health (Lond Engl), 2(1):99-114, 2006. doi: 10.2217/17455057.2.1.99

12- de Gramont A, Tournigand C, André T, Larsen AK, Louvet C. Targeted agents for

adjuvant therapy of colon cancer. Semin Oncol, 33(6 Suppl 11):S42-5, 2006.

13- Andre T, Hammel P, Lacaine F, Palazzo L, Becouarn Y, Mornex F. Cancer of the

pancreas. Gastroenterol Clin Biol, 30 Spec No 2:2S75-2S80, 2006.

22

14- Rougier P, Andre T, Panis Y, Colin P, Stremsdoerfer N, Laurent-Puig P. Colon cancer.

Gastroenterol Clin Biol, 30 Spec No 2:2S24-2S29, 2006.

15- Segura C, Afchain P, de Gramont A, André T; Gercor (French Oncology Research

Group). [Adjuvant treatment of colorectal cancer]. Bull Cancer, 93(7):683-90, 2006.

16- Mabro M, Artru P, André T, Flesch M, Maindrault-Goebel F, Landi B, Lledo G, Plantade

A, Louvet C, de Gramont A. A phase II study of FOLFIRI-3 (double infusion of

irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer

patients. Br J Cancer, 8;94(9):1287-92, 2006.

17- André T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C,

de Gramont A. Current issues in adjuvant treatment of stage II colon cancer. Ann

Surg Oncol, 13(6):887-98, 2006.

18- Hebbar M, Tournigand C, Lledo G, Mabro M, André T, Louvet C, Aparicio T, Flesch M,

Varette C, de Gramont A; Oncology Multidisciplinary Research Group (GERCOR).

Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of

patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest,

24(2):154-9, 2006.

19- Francoual M, Etienne-Grimaldi MC, Formento JL, Benchimol D, Bourgeon A, Chazal M,

Letoublon C, André T, Gilly N, Delpero JR, Lasser P, Spano JP, Milano G. EGFR in

colorectal cancer: more than a simple receptor. Ann Oncol, 17(6):962-7, 2006.

20- André T, De Gramont A. [A good cooperation between industry and French medical

oncologists]. Bull Cancer, 1;93 Suppl 1:S3-4, 2006.

21- André T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, Carola E,

Flesch M, Muron T, Boutan-Laroze A, Guérin Meyer V, Boaziz C, Maigre M, Ganem G,

Mousseau M, Mounedji-Boudiaf L, de Gramont A. [Adjuvant treatment of colon cancer

MOSAIC study's main results]. Bull Cancer, 1;93 Suppl 1:S5-9, 2006.

22- Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, André T, Ychou M,

Gamelin E, Carola E, Louvet C. Epirubicin-docetaxel in advanced gastric cancer: two

phase II studies as second and first line treatment. Bull Cancer, 93(1):E1-6, 2006.

23- Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E,

Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de

Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin

in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin

Oncol, 20;24(3):394-400, 2006.

24- Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, André T,

Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of

oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with

colorectal cancer. J Clin Oncol, 1;24(25):4085-91, 2006.

23

2005

1- Ségura C, Avenin D, Gligorov J, Selle F, Estéso A, Beerblock K, Emile G, Do Huyen N,

Lotz JP. [The use of GnRH analogues in early and advanced breast carcinomas].

Gynecol Obstet Fertil, 33(11):914-9, 2005.

2- Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz JP, Capeau J. Evaluation of

the quantitative analytical methods real-time PCR for HER-2 gene quantification and

ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization

and immunohistochemistry for determining HER-2 status in breast cancer patients.

Clin Chem, 51(7):1093-101, 2005.

3- Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, Cure JH, Orlandini C,

Ferrante P, Conte PF, Demirer T. EBMT Solid Tumor Working Party. High-dose

chemotherapy with autologous haemopoietic support for advanced ovarian cancer in

first complete remission: retrospective analysis from the Solid Tumour Registry of the

European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow

Transplant, 36(1):25-31, 2005.

4- Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J,

Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S,

Droz JP, Culine S, Biron P; Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG).

Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell

tumors combining two mobilization and cytoreductive treatments followed by three

high-dose chemotherapy regimens supported by autologous stem cell transplantation.

Results of the phase II multicentric TAXIF trial. Ann Oncol, 16(3):411-8, 2005.

5- Lotz JP, Curé H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P,

Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S,

Maraninchi D, Roché H, Gisselbrecht C. High-dose chemotherapy with haematopoietic

stem cell transplantation for metastatic breast cancer patients: final results of the

French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer, 41(1):71-

80, 2005.

6- Nabholtz JM, Gligorov J. Docetaxel in the treatment of breast cancer: current

experience and future prospects. Expert Rev Anticancer Ther, 5(4):613-33, 2005.

7- Nabholtz JM, Gligorov J. Docetaxel/trastuzumab combination therapy for the

treatment of breast cancer. Expert Opin Pharmacother, 6(9):1555-64, 2005.

8- Nabholtz JM, Gligorov J. The role of taxanes in the treatment of breast cancer.

Expert Opin Pharmacother, 6(7):1073-94, 2005.

9- Molinari E, De Quatrebarbes J, André T, Aractingi S. Cetuximab-induced acne.

Dermatology, 211(4):330-3, 2005.

10- Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz

JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr

D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival

versus overall survival as a primary end point for adjuvant colon cancer studies:

individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol,

1;23(34):8664-70, 2005.

24

11- Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De

Gramont A. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

Eur J Cancer, 41(15):2262-7, 2005.

12- Coudray AM, Louvet C, Kornprobst M, Raymond E, André T, Tournigand C, Faivre S,

De Gramont A, Larsen AK, Gespach C. Increased anticancer activity of the

thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor

SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK

cleavage through caspase-3-dependent and –independent mechanisms. Int J Oncol,

27(2):553-61, 2005.

13- Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A,

Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in

locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD

phase III trial. J Clin Oncol, 20;23(15):3509-16, 2005.

14- de Gramont A, Tournigand C, Louvet C, Maindrault-Goebel F, André T. First-line

therapy for advanced colorectal cancer. Curr Oncol Rep, 7(3):167-72, 2005.

15- Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM,

Tournigand C, Parc R, de Gramont A. Intensive systemic chemotherapy combined

with surgery for metastatic colorectal cancer: results of a phase II study. J Clin

Oncol, 20;23(3):502-9, 2005.

25

2004 1- Gligorov J, Debourdeau P, Arsovski O, Lotz JP. [Cardiac prevention: the oncologic

point of view]. Bull Cancer, 91 Suppl 3:192-200, 2004.

2- Saintigny P, Assouad S, Gligorov J, Selle F, Roché H, Breau JL, Morère JF, Lotz JP.

[Dose density and dose intensity in the treatment of breast cancer]. Bull Cancer,

1;91 Suppl 4:S244-53, 2004.

3- Debrix I, André T, Becker A, Lotz JP, Gligorov J, Boukari Y, Milleron B, Pene F,

Flahault A. [Anticancer drugs off label used of: what do the experts think about?].

Bull Cancer, 91(10):769-77, 2004.

4- André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D,

Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C;

GERCOR Group. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary

tract adenocarcinoma: a GERCOR study. Ann Oncol, 5(9):1339-43, 2004.

5- Debrix I, André T, Flahault A, Kalu O, Gligorov J, Lotz JP, Milleron B, Pene F, Boukari

Y, Becker A. [Anticancer drugs use evaluation: limits of the approved labeling]. Bull

Cancer, 91(5):437-43, 2004.

6- Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the

differences. Oncologist, 4;9 Suppl 2:3-8, 2004.

7- Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. [18F]FDG in recurrent

breast cancer: diagnostic performances, clinical impact and relevance of induced

changes in management. Eur J Nucl Med Mol Imaging, 31(2):179-88, 2004.

8- Gholam D, Lotz JP, Atallah D, Theodore C. Germ cell tumors. Case 2. Unusual course

of pure testicular seminoma. J Clin Oncol, 1;22(9):1755-6, 2004.

9- Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C. [Malignant cardiac tumors].

Bull Cancer, 91 Suppl 3:136-46, 2004.

10- Debourdeau P, Bachelot T, Zammit C, Aletti M, Gallineau C, Gligorov J. [Treatment of

hot flashes in women with a previous diagnosis of breast cancer]. Bull Cancer,

91(4):339-49, 2004.

11- André T, Noirclerc M, Hammel P, Meckenstock R, Landi B, Cattan S, Selle F, Codoul

JF, Guerrier-Parmentier B, Mokhtar R, Louvet C; GERCOR. Phase II study of

leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic

pancreatic cancer (FOLFUGEM 2). Gastroenterol Clin Biol, 28(8-9):645-50, 2004.

12- André T, Soria JC. [Cyclo-oxygenase 2 inhibitors and cancer]. Bull Cancer, 91 Suppl

2:S59-60, 2004.

13- Louvet C, André T, Gamelin E, Garcia ML, Saavedra A, Lenaers G, de Gramont A,

Méry-Mignard D, Kalla S. A phase I-II, dose-escalating trial of ZD9331 in combination

with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

Bull Cancer, 91(12):279-84, 2004.

14- Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y,

Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC,

Palmer PA. Phase III double-blind placebo-controlled study of farnesyl transferase

inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin

Oncol, 1;22(19):3950-7, 2004.

15- Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, Louvet C,

de Gramont A. Oxaliplatin reintroduction in patients previously treated with

26

leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol,

15(8):1210-4, 2004.

16- André T, Soria JC. [Cyclo-oxygenase 2 inhibitors and cancer]. Bull Cancer, 91 Spec

No:S59-60, 2004.

17- Andre T, de Gramont A; Study Group of Clinical Research in Radiotherapies Oncology,

Oncology Multidiciplinary Research Group. An overview of adjuvant systemic

chemotherapy for colon cancer. Clin Colorectal Cancer, 4 Suppl 1:S22-8, 2004.

18- André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C,

Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Multicenter

International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant

Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and

leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 3;350(23):2343-

51, 2004.

19- André T, Louvet C, de Gramont A. [Colon cancer: what is new in 2004?]. Bull

Cancer, 91(1):75-80, 2004.

20- Perez N, Tournigand C, Mabro M, Molitor JL, Artru P, Carola E, André T, Louvet C,

Krulik M, de Gramont A. [Long term survival in metastatic colorectal cancer treated

with leucovorin and 5-fluoro-uracil chemotherapy]. Rev Med Interne, 25(2):124-8,

2004.

21- Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E,

Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIR

followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a

randomized GERCOR study. J Clin Oncol, 15;22(2):229-37, 2004.

27

2003

1- Selle F, Hugue F, Lotz JP. [Diagnosis of cancer. Signs and paraclinical investigations;

stratification; prognosis]. Rev Prat, 15;53(6):647-56, 2003.

2- Moulin AS, Lotz JP. [Cancer and the law]. Bull Cancer, 90(1):105-12, 2003.

3- Roche H, Viens P, Biron P, Lotz JP, Asselain B; PEGASE Group. High-dose

chemotherapy for breast cancer: the French PEGASE experience. Cancer Control,

10(1):42-7, 2003.

4- Gligorov J, Beuzeboc P. [From San Antonio to Saint-Gallen: reflections of Saint-Paul-

de-Venice or how to treat breast cancer]. Bull Cancer, 90(3):278-83, 2003.

5- Plantade A, Montravers F, Selle F, Izrael V, Talbot JN. Diffusely increased F-18 FDG

uptake in bone marrow in a patient with acute anemia and recent erythropoietin

therapy. Clin Nucl Med, 28(9):771-2, 2003.

6- Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M,

Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C,

Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative

Group. Subcutaneous interleukin-2 and interferon alfa administration in patients with

metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase

II, nonrandomized study with sequential analysis design--the Subcutaneous

Administration Propeukin Program Cooperative Group. J Clin Oncol, 1;21(21):3987-

94, 2003.

7- Scurtu R, Barrier A, André T, Houry S, Huguier M. [Self-expandable metallic stent for

palliative treatment of colorectal malignant obstructions: risk of perforation]. Ann

Chir, 128(6):359-63, 2003.

8- Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C,

Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for

24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a

randomized trial. J Clin Oncol, 1;21(15):2896-903, 2003.

9- Mabro M, Louvet C, André T, Carola E, Gilles-Amar V, Artru P, Krulik M, de Gramont

A; GERCOR. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and

irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol,

26(3):254-8, 2003.

10- Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, André T,

Gamelin E, de Gramont A. Prognostic factor analysis in advanced gastric cancer

patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP

regimen). Cancer Invest, 21(1):14-20, 2003.

11- André T, Bossard C, Gattegno B, Plouin PF, Benoit G, Richard S. A type 2B von

Hippel-Lindau family masquerading as a metastatic sporadic renal cell carcinoma.

BJU Int, 91(4):425-6, 2003.

28

2002

1- Gligorov J, André T, Epaud C, Culine S. [Updates on gemcitabine at the American

Society of Clinical Oncology congress (ASCO, 2002)]. Bull Cancer, 89 Spec No:S134-

44, 2002.

2- Hoff A, André T, Schäffer TE, Jung G, Wiesmüller KH, Brock R. Lipoconjugates for the

noncovalent generation of microarrays in biochemical and cellular assays.

Chembiochem, 2;3(12):1183-91, 2002.

3- Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob

JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A. Phase II study of

oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric

cancer patients. J Clin Oncol, 1;20(23):4543-8, 2002.

4- Gligorov J, André T, Epaud C, Culine S. [Updates on gemcitabine at the American

Society of Clinical Oncology congress (ASCO, 2002)]. Bull Cancer, 89 Spec No:S134-

44, 2002.

5- Louvet C, André T, Artru P. [Gemcitabine-based combinations in inoperable

pancreatic cancers]. Bull Cancer, 89 Spec No:S96-101, 2002.

6- André T. [Congress of the American Society of Clinical Oncology]. J Chir (Paris),

139(5):300-3, 2002.

7- Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C,

Kornprobst M, André T, Mareel M, Mester J, Gespach C. The c-kit tyrosine kinase

inhibitor STI571 for colorectal cancer therapy. Cancer Res, 1;62(17):4879-83, 2002.

8- Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M,

Cvitkovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced

pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J

Clin Oncol, 15;20(6):1512-8, 2002.

29

2001

1- Dal Cortivo L, Cottu PH, Lotz JP, Robert I, Extra JM, Miclea JM, Marty M, Marolleau

JP. Residual tumor cell contamination in peripheral blood stem cells collections of 117

breast cancer patients evaluated by immunocytochemical technique. J Hematother

Stem Cell Res, 10(6):855-62, 2001.

2- Trillet-Lenoir V, Lotz JP, Le Cesne A, Roy P, Avallet L, Edouard A. Reflexions from the

experience of the French CLEOPATRE program and concerns about the status of

clinical research on small cell lung cancer. Lung Cancer, 33(2-3):303-7, 2001.

3- Pujade-Lauraine E, Curé H, Battista C, Guastalla JP, Chiurazzi B, Fabbro M,Tubiana-

Mathieu N, Bourgeois H, Lioure B, Paraiso D, Lotz JP. High dosechemotherapy in

ovarian cancer. Int J Gynecol Cancer, 11 Suppl 1:64-7, 2001.

4- Ledermann JA, Herd R, Maraninchi D, Viens P, Buclon M, Philip T, Cure H, Lotz JP,

Chauvin F, Ferrante P, Rosti G. High-dose chemotherapy for ovarian carcinoma: long-

term results from the Solid Tumour Registry of the European Group for Blood and

Marrow Transplantation (EBMT). Ann Oncol, 12(5):693-9, 2001.

5- Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, Artru P,

Gilles V, Lotz JP, Izrael V, Krulik M; Oncology Multidisciplinary Research Group

(GERCOR). High-dose intensity oxaliplatin added to the simplified bimonthly

leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal

cancer (FOLFOX 7). Eur J Cancer, 37(8):1000-5, 2001.

6- Dosquet C, Chen Y, Makke J, Miclea JM, Coudert MC, Marolleau JP, Fermand JP, Cottu

P, Lotz JP, Benbunan M. Cytokines and vascular cell adhesion molecule-1 in the blood

of patients undergoing HPC mobilization. Transfusion, 41(2):206-12, 2001.

7- André T, Louvet C, Maindrault-Goebel F, Gramont AD. [Oxaliplatin in combination

with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. Bull

Cancer, 88 Spec No:S20-5, 2001.

8- Louvet C, André T, Hammel P, Selle F, Landi B, Cattan S, Fonck M, Flesch M, Colin P,

Balosso J, Ruszniewski P, de Gramont A. Phase II trial of bimonthly leucovorin, 5-

fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

Ann Oncol, 12(5):675-9, 2001.

9- André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C,

Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Billiau V, Buyse M,

Gramont A; Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin

in stage B2 and C colon adenocarcinoma: study design and preliminary safety results.

Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. Semin

Oncol, 28(1 Suppl 1):35-40, 2001.

30

2000 1- Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP,

Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of

oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil

continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer.

Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol, 11(11):1477-83,

2000.

2- Lotz JP, Gligorov J, Selle F, Lefevre G, Pautier P, Lhommé C. [High dose

chemotherapy in ovarian and breast adenocarcinoma with poor prognosis]. Gynecol

Obstet Fertil, 28(9):620-31, 2000.

3- Yanovich S, Mitsky P, Cornetta K, Maziarz RT, Rosenfeld C, Krause DS, Lotz JP, Bitran

JD, Williams S, Preti R, Somlo G, Burtness B, Mills B. Transplantation of CD34+

peripheral blood cells selected using a fully automated immunomagnetic system in

patients with high-risk breast cancer: results of a prospectiverandomized multicenter

clinical trial. Bone Marrow Transplant, 25(11):1165-74, 2000.

4- André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP,

De Gramont A, Bellaïche A, Parc R, Touboul E, Izrael V. Combined radiotherapy and

chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized

unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results

of a feasibility study. Int J Radiat Oncol Biol Phys, 1;46(4):903-11, 2000.

5- Lotz JP, Lhommé C, Pautier P, Couteau C, Gligorov J, Alexandre J, Selle F, Izrael V,

Maraninchi D, Viens P. [High-dose chemotherapy in ovarian adenocarcinoma]. Bull

Cancer, 87(1):63-9, 2000.

6- Clézardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor

cells and prospects for use in the treatment of malignant osteolysis. Joint Bone

Spine, 67(1):22-9, 2000.

7- Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP,

Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of

oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil

continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer.

Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol, 11(11):1477-83,

2000.

8- André T, Houry S. [36th Congress of the American Society of Clinical Oncology

(ASCO). New Orleans 20-23 May 2000]. J Chir (Paris), 137(4):251-4, 2000.

9- André T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prévot S, Parc R, Gespach

C, Chastre E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during

the neoplastic progression of human colonic mucosa. Int J Cancer, 15;86(2):174-

81, 2000.

31

1999

1- Ghazli M, Sananes S, Chopier J, Touboul E, Lotz JP, Antoine M, Antoine JM, Uzan S.

[Inflammatory and/or locally advanced breast cancers. Difficulty evaluating the

response to initial chemotherapy]. Contracept Fertil Sex, 27(12):872-6, 1999.

2- André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V,

Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly,

high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for

pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35(9):1343-7,

1999.

3- Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML,

Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Oxaliplatin added to the simplified

bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic

colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer, 35(9):1338-42, 1999.

4- Lotz JP, Lecesne A, Trillet-Lenoir V. [The Cleopatra project]. Rev Pneumol Clin,

55(4):234-5, 1999.

5- Lotz JP, Curé H, Janvier M, Morvan F, Legros M, Asselain B, Guillemot M, Roché H,

Gisselbrecht C. [Intensive chemotherapy and autograft of hematopoietic stem cells in

the treatment of metastatic cancer: results of the national protocol Pegase 04].

Hematol Cell Ther, 41(2):71-4, 1999.

6- Edelman L, Durand JC, Lotz JP, Validire P, Monchâtre E, Bayle C, Arnoulet C, Sainty

D. Remote tumor cells in the case of breast cancers: significance of their presence for

prognosis [corrected]. Hematol Cell Ther, 41(2):66-70, 1999.

7- Marolleau JP, Dal Cortivo L, Mills B, Fermand JP, Miclea JM, Lotz JP, Gisselbrecht C,

Benbunan M. Enrichment of peripheral blood CD34+ cells for transplantation using a

fully automated immunomagnetic cell selection system and a novel octapeptide

releasing agent. Bone Marrow Transplant, 23(8):819-26, 1999.

8- Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J,

Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.

Local recurrences and distant metastases after breast-conserving surgery and

radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys,

1;43(1):25-38, 1999.

9- Gligorov J, Couteau C, Debourdeau P, Antoine M, Pene F, Milleron B. [Small cell lung

carcinoma]. Bull Cancer, Suppl 3:5-16, 1999.

10- Debourdeau P, Gligorov J, Zammit C. A serologic marker of paraneoplastic limbic and

brain-stem encephalitis in patients with testicular cancer. N Engl J Med,

4;341(19):1475-6, 1999.

11- André T, Balosso J. [Chemotherapy, combined radiochemotherapy and new

therapeutic approaches in adenocarcinoma of the pancreas]. J Chir (Paris),

136(6):309-17, 1999.

12- André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V,

Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly,

high-dose leucovorin and bolus and continuous-infusio 5-fluorouracil (FOLFIRI) for

pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35(9):1343-7,

1999.

32

13- Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML,

Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Oxaliplatin added to the simplified

bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic

colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer, 35(9):1338-42, 1999.

14- Brienza S, Bensmaïne MA, Soulié P, Louvet C, Gamelin E, François E, Ducreux M,

Marty M, André T, de Braud F, Bleiberg H, Ségal V, Itzhaki M, Cvitkovic E. Oxaliplatin

added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-

pretreated patients with advanced colorectal carcinoma (ACRC): results from the

European compassionate-use program. Ann Oncol, 10(11):1311-6, 1999.

15- André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, BeerblockK,

Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion,

and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and

fluorouracil regimen. J Clin Oncol,17(11):3560-8, 1999.

33

1998

1- André T, Balosso J, Louvet C, Houry S, Vaillant JC, Touboul E, Lotz JP, de Gramont A,

Izrael V. [Adenocarcinoma of the pancreas. Therapeutic strategies]. Presse Med,

21;27(11):539-45, 1998.

2- Chabannon C, Cornetta K, Lotz JP, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau

JP, Sledge G, Novakovitch G, Srour EF, Burtness B, Camerlo J, Gravis G, Lee-Fischer

J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise

D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+

peripheral blood cells in patients with poor-prognosis breast cancer: a randomized

multicentre study. Br J Cancer, 78(7):913-21, 1998.

3- Moreau P, Fleury J, Brice P, Colombat P, Bouabdallah R, Lioure B, Voillat L,

Casasnovas O, François S, Sadoun A, Lamy T, Lotz JP, Munck JN, Divine M, Fermé C,

Pény AM, Fruchart C, Oriol P, Ojeda M, Reman O, Milpied N, Gisselbrecht C, Legros

M, Harousseau JL. Early intensive therapy with autologous stem cell transplantation

in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French

registry. Bone Marrow Transplant, 21(8):787-93, 1998.

4- Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three

patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry,

64(5):667-9, 1998.

5- André T, Balosso J, Louvet C, Gligorov J, Couteau C, Avenin D, de Gramont A, Izrael

V. [Adenocarcinoma of the pancreas. Diagnosis and evaluation]. Presse Med,

21;27(11):537-8, 1998.

6- André T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, Izrael V.

[Adenocarcinoma of the pancreas. General characteristics]. Presse Med,

21;27(11):533-6, 1998.

7- Debourdeau P, Gligorov J, Couteau C. Genetic abnormalities in synovial sarcoma. N

Engl J Med, 4;338(23):1699, 1998.

8- Ducreux M, Gil-Delgado M, André T, Ychou M, de Gramond A, Khayat D. [Irinotecan

in combination for colon cancer]. Bull Cancer, Spec No:43-6, 1998.

9- André T, Chastre E, Kotelevets L, Vaillant JC, Louvet C, Balosso J, Le Gall E, Prévot S,

Gespach C. [Tumoral angiogenesis: physiopathology, prognostic value and

therapeutic perspectives]. Rev Med Interne, 19(12):904-13, 1998.

10- André T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose

leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal

cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol,

9(11):1251-3, 1998.

11- André T, Balosso J, Louvet C, Houry S, Vaillant JC, Touboul E, Lotz JP, de Gramont A,

Izrael V. [Adenocarcinoma of the pancreas. Therapeutic strategies]. Presse Med,

21;27(11):539-45, 1998.

12- André T, Balosso J, Louvet C, Gligorov J, Couteau C, Avenin D, de Gramont A, Izrael

V. [Adenocarcinoma of the pancreas. Diagnosis and evaluation]. Presse Med,

21;27(11):537-8, 1998.

34

13- André T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, Izrael V.

[Adenocarcinoma of the pancreas. General characteristics]. Presse Med,

21;27(11):533-6, 1998.

14- Houry S, Gharbi L, Huguier M, Callard P, André T. [Undifferentiated embryonal

sarcoma in the liver of adults]. Presse Med, 21;27(11):518-20, 1998.

15- de Gramont A, Louvet C, André T, Tournigand C, Krulik M. A review of GERCOD trials

of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced

colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les

Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer, 34(5):619-26, 1998.

35

1997

1- Debourdeau P, Gros P, Lotz JP, Gligorov J, Vaylet F, Merrer J, Berets O. [Synovial

sarcoma. Epidemiologic and histologic data, prognostic factors and treatment].

Presse Med, 6;26(38):1867-73, 1997.

2- Gligorov J, Debourdeau P, Lotz JP. Endometriosis and non-Hodgkin's lymphoma. Am

J Obstet Gynecol, 177(5):1274-5, 1997.

3- Lotz JP, Chapiro J, Voinea A, Cornu P, Péne F, Bazelly B, Similowski T, Derquenne F.

Overdosage of vinorelbine in a woman with metastatic non-small-cell lung carcinoma.

Ann Oncol, 8(7):714-5, 1997.

4- Debourdeau P, Gros P, Lotz JP, Gligorov J, Vaylet F, Merrer J, Berets O.[Synovial

sarcoma. Epidemiologic and histologic data, prognostic factors and treatment].

Presse Med, 6;26(38):1867-73, 1997.

5- Gligorov J, Debourdeau P, Lotz JP. Endometriosis and non-Hodgkin's lymphoma. Am

J Obstet Gynecol, 177(5):1274-5, 1997.

6- Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escrieut C, Kennedy K, Vaysse N,

Gespach C, Fourmy D. Differential expression of the CCK-A and CCK-B/gastrin

receptor genes in human cancers of the esophagus, stomach and colon. Int J

Cancer, 17;72(6):931-6, 1997.

7- Beerblock K, Rinaldi Y, André T, Louvet C, Raymond E, Tournigand C, Carola E, Favre

R, de Gramont A, Krulik M. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour

continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude

et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Cancer,

15;79(6):1100-5, 1997.

8- de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E,

Moreau S, Le Bail N, Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil

48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J

Cancer, 33(2):214-9, 1997.

9- de Gramont A, Tournigand C, Louvet C, André T, Molitor JL, Raymond E, Moreau S,

Vignoud J, Le Bail N, Krulik M. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in

pretreated patients with metastatic advanced cancer. The GERCOD]. Rev Med

Interne, 18(10):769-75, 1997.

10- de Gramont A, Louvet C, André T, Tournigand C, Raymond E, Molitor JL, Krulik M.

[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe

d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]. Rev Med

Interne, Suppl 4:372s-378s, 1997.

11- Coutant G, Algayres JP, Dordain ML, Selle F, Le Berruyer PY, Bili H, Daly JP.

[Antiandrogen withdrawal syndrome in hormone refractory metastatic prostate

cancer]. Rev Med Interne, 18(9):732-4, 1997.

36

1996

1- Lotz JP, Pène F, Bouleuc C, André T, Macovei C, Laadem A, Debourdeau P, Gumus Y,

Merad Z, Avenin D, Esteso A, Bellaiche A, Izrael V. [Therapeutic intensification and

autotransplantation of hematopoietic stem cells in metastatic breast cancers]. Presse

Med, 16;25(35):1737-43, 1996.

2- Gisselbrecht C, Extra JM, Lotz JP, Devaux Y, Janvier M, Peny AM, Guillevin L,

Bremond D, Delain M, Herbrecht R, Lepage E, Maraninchi D.

Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone

marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow

Transplant, 18(5):857-63, 1996.

3- Lotz JP, André T, Bouleuc C, Péne F, Gattegno B, Bazelly B, Houry S, Chapiro J, Selle

F, Gligorov J, Izrael V. The ICE regimen (ifosfamide, carboplatin, etoposide) for the

treatment of germ-cell tumors and metastatic trophoblastic disease. Bone Marrow

Transplant, 18 Suppl 1:S55-9, 1996.

4- Gisselbrecht C, Viens P, Lotz JP, Biron P, Asselain B, Maraninchi D, Roché H. "Pegase"

program for evaluation of autologous stem cell transplantation in breast cancer.

SFGM and PEGASE Group. Bone Marrow Transplant, 18 Suppl 1:S21-3, 1996.

5- Lotz JP, Bouleuc C, André T, Touboul E, Macovei C, Hannoun L, Lefranc JP, Houry S,

Uzan S, Izrael V. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and

teniposide with autologous bone marrow transplantation for the treatment of poor

prognosis common epithelial ovarian carcinoma. Cancer, 15;77(12):2550-9, 1996.

6- Lotz JP, Pene F, Bouleuc C, André T, Gligorov J, Avenin D, Esteso A, Bellaiche A,

Macovei C, Merad Z, Laadem A, Vanica R, Izrael V. [High-dose therapy and

hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors].

Contracept Fertil Sex. 1996 Apr;24(4):307-18. Review. French. PubMed 83: André T,

Lotz JP, Bouleuc C, Azzouzi K, Houry S, Hannoun L, See J, Esteso A, Avenin D, Izrael

V. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced

pancreatic adenocarcinoma. Ann Oncol, 7(2):173-8, 1996.

7- Tsatsaris V, Lotz JP, Parrot A, André T, Lafont B, Bouleuc C, Antoine M, Izrael V.

[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a

case. Review of the literature]. Rev Med Interne, 17(9):749-53, 1996.

8- Antoine JM, André T, Antoine M, Lotz JP, Salat-Baroux J. [Mulleroblastoma of the

uterus. Role of chemotherapy. A case report]. J Gynecol Obstet Biol

Reprod(Paris), 25(1):53-5, 1996.

9- Lotz JP, André T, Bouleuc C, Péne F, Gattegno B, Bazelly B, Houry S, Chapiro J, Selle

F, Gligorov J, Izrael V. The ICE regimen (ifosfamide, carboplatin, etoposide) for the

treatment of germ-cell tumors and metastatic trophoblastic disease. Bone Marrow

Transplant, 18 Suppl 1:S55-9, 1996.

10- Lotz JP, Pene F, Bouleuc C, André T, Gligorov J, Avenin D, Esteso A, Bellaiche A,

Macovei C, Merad Z, Laadem A, Vanica R, Izrael V. [High-dose therapy and

hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors].

Contracept Fertil Sex, 24(4):307-18, 1996.

11- Meynard JL, Lalande V, Selle F, Guiguet M, Meyohas MC, Picard O, Duvivier C, Petit

JC, Frottier J. [Acid-alcohol-resistant bacilli detected by microscopic analysis of

37

exhaled air from HIV-infected patients: tuberculosis or mycobacteriosis?]. Presse

Med, 10;25(5):193-6, 1996.

12- Lotz JP, Pène F, Bouleuc C, André T, Macovei C, Laadem A, Debourdeau P, Gumus Y,

Merad Z, Avenin D, Esteso A, Bellaiche A, Izrael V. [Therapeutic intensification and

autotransplantation of hematopoietic stem cells in metastatic breast cancers]. Presse

Med, 16;25(35):1737-43, 1996.

13- de Gramont A, Louvet C, André T, Tournigand C, Raymond E, Krulik M.

[Chemotherapy of colorectal cancers with metastases]. Presse Med,

16;25(35):1678-82, 1996.

14- Lotz JP, André T, Bouleuc C, Péne F, Gattegno B, Bazelly B, Houry S, Chapiro J, Selle

F, Gligorov J, Izrael V. The ICE regimen (ifosfamide, carboplatin, etoposide) for the

treatment of germ-cell tumors and metastatic trophoblastic disease. Bone Marrow

Transplant, 18 Suppl 1:S55-9, 1996.

15- Lotz JP, Bouleuc C, André T, Touboul E, Macovei C, Hannoun L, Lefranc JP, Houry S,

Uzan S, Izrael V. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and

teniposide with autologous bone marrow transplantation for the treatment of poor

prognosis common epithelial ovarian carcinoma. Cancer, 15;77(12):2550-9, 1996.

16- Le Parc JM, André T, Helenon O, Benoit J, Paolaggi JB, Kreis H. Osteonecrosis of the

hip in renal transplant recipients. Changes in functional status and magnetic

resonance imaging findings over three years in three hundred five patients. Rev

Rhum Engl Ed, 63(6):413-20, 1996.

17- André T, Lotz JP, Bouleuc C, Azzouzi K, Houry S, Hannoun L, See J, Esteso A, Avenin

D, Izrael V. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of

advanced pancreatic adenocarcinoma. Ann Oncol, 7(2):173-8, 1996.

18- Tsatsaris V, Lotz JP, Parrot A, André T, Lafont B, Bouleuc C, Antoine M, Izrael V.

[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a

case. Review of the literature]. Rev Med Interne, 17(9):749-53, 1996.

19- Antoine JM, André T, Antoine M, Lotz JP, Salat-Baroux J. [Mulleroblastoma of the

uterus. Role of chemotherapy. A case report]. J Gynecol Obstet Biol Reprod

(Paris), 25(1):53-5, 1996.

38

1995

1- Lotz JP, Izrael V. Phase I study of high-dose ifosfamide, carboplatin and etoposide

with autologous hematopoietic stem cell support. Bone Marrow Transplant,

16(6):858-9, 1995.

2- Pavlovic M, Saiag P, Lotz JP, Marinho E, Clerici T, Izrael V. Regression of

sclerodermatous skin lesions in a patient with carcinoid syndrome treated by

octreotide. Arch Dermatol, 131(10):1207-9, 1995.

3- Farhat F, Culine S, Lhomme C, Duvillard P, Terrier-Lacombe MJ, Michel G, Soulie P,

Theodore C, Lotz JP, Droz JP. [Desmoplastic small round cell tumors in adults: a new

entity]. Bull Cancer, 82(8):665-73, 1995.

4- Lotz JP, André T, Donsimoni R, Firmin C, Bouleuc C, Bonnak H, Merad Z, Esteso A,

Gerota J, Izrael V. High dose chemotherapy with ifosfamide, carboplatin, and

etoposide combined with autologous bone marrow transplantation for the treatment

of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.

Cancer, 1;75(3):874-85, 1995.

5- Lotz JP, Pene F, Bouleuc C, André T, Gisselbrecht C, Bonnak H, Merad Z, Esteso A,

Miccio-Bellaiche A, Avenin D, et al. [Therapeutic intensification and hematopoietic

stem cell autotransplantation in the treatment of solid tumors in adults. Principles,

realization, and application to the treatment of germinal, trophoblastic, breast,

ovarian and small-cell bronchial tumors. 2]. Rev Med Interne, 16(2):150-62, 1995.

6- Chassagne P, Gligorov J, Dominique S. Pulmonary artery obstruction and giant cell

arteritis. Ann Intern Med, 1;122(9):732, 1995.

39

1994

1- Bazelly B, Lotz JP, Milleron B. [The maintenance of totally implantable perfusion

sites]. Rev Pneumol Clin. 1994;50(1):43-4.

2- Lotz JP, Grange JD, Hannoun L, Boudghene F, Amiot X, Lamarque D, Andre T, Esteso

A, Bellaiche A, Bouleuc C, et al. Treatment of unresectable hepatocellular carcinoma

with a combination of human recombinant alpha-2b interferon and doxorubicin:

results of a pilot study. Eur J Cancer. 1994;30A(9):1319-25.

3- Holland A, Andre T. The relationship of self-esteem to selected personal and

environmental resources of adolescents. Adolescence. 1994 Summer;29(114):345-60.

40

1993

1- Chopier-Richaud J, Ouahes N, Breittmayer F, Lotz JP, Bigot JM. [Digestive carcinoid

tumors]. J Chir (Paris). 1993 Nov;130(11):475-8.

2- Chopier-Richaud J, Ouahes N, Breittmayer F, Lotz JP, Bigot JM. [Digestive carcinoid

tumors]. J Radiol. 1993 May;74(5):279-82.

3- Machover D, Grison X, Goldschmidt E, Zittoun J, Metzger G, Richaud J, Lotz JP, André

T, Hannoun L, Marquet J, et al. 5-Fluorouracil combined with the [6S]-stereoisomer

of folinic acid in high doses for treatment of patients with advanced colorectal

carcinoma. A phase I-II study of two consecutive regimens. Ann Oncol. 1993;4 Suppl

2:29-35.

4- Machover D, Grison X, Goldschmidt E, Zittoun J, Lotz JP, Metzger G, Richaud J,

Hannoun L, Marquet J, Guillot T, et al. 5-Fluorouracil combined with the pure [6S]-

stereoisomer of folinic acid in high doses for treatment of patients with advanced

colorectal carcinoma: a phase I-II study of two consecutive regimens. Adv Exp Med

Biol. 1993;339:81-95; discussion 97-8.

5- Machover D, Grison X, Goldschmidt E, Zittoun J, Lotz JP, Metzger G, Richaud J,

Hannoun L, Marquet J, Guillot T, et al. Fluorouracil combined with the pure (6S)-

stereoisomer of folinic acid in high doses for treatment of patients with advanced

colorectal carcinoma: a phase I-II study. J Natl Cancer Inst. 1992 Mar 4;84(5):321-7.

41

1991

1- Lotz JP, Machover D, Malassagne B, Hingh B, Donsimoni R, Gumus Y, Gerota J,

Lam Y, Tulliez M, Marsiglia H, et al. Phase I-II study of two consecutive courses of high-dose

epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow

transplantation for treatment of adult patients with solid tumors. J Clin Oncol. 1991

Oct;9(10):1860-70.

2- Amiot X, Grangé JD, Boudghene F, Lamarque D, Lotz JP, Izrael V, Bodin F.

[Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and

recombinant human alpha-2 interferon]. Ann Gastroenterol Hepatol (Paris). 1991

Oct;27(5):211-4.

42

1990

1- Chopier-Richaud J, Rolloy P, Le Breton C, Tibi C, Lotz JP, Bigot JM. [Ovarian

metastases in transposed ovaries: x-ray computed tomographic aspect. Report of a

case]. Ann Radiol (Paris). 1990;33(6):351-3.